US Cosmetics Companies Doing Gap Analysis, Awaiting FDA Instruction In MoCRA’s First Year
Executive Summary
Amin Talati Wasserman attorney Angela Diesch discusses the priorities, questions and concerns among companies facing end-of-year deadlines under the Modernization of Cosmetic Regulations Act enacted in the final days of 2022.
You may also be interested in...
Cosmetic Manufacturers Preparing For MoCRA Safety Substantiation Should Look To EU – Attorneys
Manufacturers looking for a model of safety substantiation in order to comply with the US Modernization of Cosmetics Regulation Act of 2022 should consider the framework required by the EU’s Cosmetic Products Regulation, says Steptoe & Johnson associate Surya Kundu. Attorneys also discussed new requirements for adverse event reporting during a FDLI webinar on MoCRA.
FDA’s Linda Katz Addresses Why VCRP Wouldn’t Work For Cosmetics Registration Under MoCRA
The cosmetics office director assured attendees of a 27 April FDLI webinar that the agency’s launch of a new platform for cosmetics registration and product listing will afford companies sufficient time to comply with new requirements under the Modernization of Cosmetic Regulations Act.
MoCRA Check-In: FDA Guidance Urgently Needed As Year-End Compliance Deadlines Loom
John Bailey, independent advisor for colors and cosmetics at EAS Consulting Group, is checking in with HBW Insight periodically in 2023 to offer his views on developments under the US Modernization of Cosmetic Regulations Act of 2022. Here he discusses the urgent need for FDA guidance as deadlines creep closer for registration, product listing, safety substantiation, and adverse event reporting.